FDA Needs Earlier Reports On Sponsors’ Ties To Trial Investigators, OIG Says
This article was originally published in The Gray Sheet
Executive Summary
Industry sponsors of device and drug studies should disclose to FDA all of their financial relationships with the researchers before the trials even begin, according to a January 2009 1report by HHS' Office of Inspector General
You may also be interested in...
Clinical Investigators' Financial Disclosures Might Become Public – Guidance
FDA is signaling greater readiness to publicly disclose what was once considered proprietary information on the financial ties of clinical trial investigators.
Clinical Investigators' Financial Disclosures Might Become Public – Guidance
FDA is signaling greater readiness to publicly disclose what was once considered proprietary information on the financial ties of clinical trial investigators.
New Jersey Attorney General Targets Industry Ties To Clinical Investigators
The attorney general of New Jersey is going after the device industry for failures to disclose possible financial conflicts of interest with clinical trial investigators, and wants FDA to strengthen its enforcement, as well